Stock of the Day

argenx (ARGX)

$588.52

+$7.93 (+1.4%)

Market Cap: $35.95B

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

• The current stock price is around $576, which may present a buying opportunity for investors looking for growth in the biotech sector.
• Institutional investors own over 60% of argenx SE, indicating strong confidence from major financial players in the company's future prospects.
• Recent analyst upgrades have set a consensus price target of approximately $709.18, suggesting potential upside for investors.
• Multiple research firms have issued "buy" ratings, reflecting positive sentiment and expectations for the company's performance.
• argenx SE has shown significant stock performance with a twelve-month high of $678.21, demonstrating its growth potential in the market.

argenx Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

• The stock has experienced volatility, with a twelve-month low of $361.26, which may concern risk-averse investors.
• The price-to-earnings ratio is notably high at -655.39, indicating that the company is not currently profitable, which could deter some investors.
• Recent trading activity shows a decline of about 0.7%, suggesting potential short-term weakness in the stock's performance.
• Some hedge funds have reduced their holdings, which may signal a lack of confidence in the company's near-term outlook.
• Despite positive ratings, one analyst has issued a hold rating, indicating that not all market experts are fully optimistic about the stock's future performance.

Recent News

• Barclays Boosts Argenx (ARGX) PT to EUR 680 After Strong Q1 2025 Performance (msn.com)
• argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference (globenewswire.com)